Abilify: use in bipolar disorder extended

Abilify is now indicated for the treatment of moderate to severe manic episodes in adolescents aged 13 years and older with bipolar I disorder.

Abilify (aripiprazole) offers an alternative atypical antipsychotic for the treatment of manic episides in adolescents with bipolar disorder.
Abilify (aripiprazole) offers an alternative atypical antipsychotic for the treatment of manic episides in adolescents with bipolar disorder.

Doses of the antipsychotic should be titrated as follows: 2mg daily for 2 days then 5mg daily for 2 days, followed by the usual maintenance dose of 10mg once daily for a maximum duration of 12 weeks.

Study design

The efficacy of aripiprazole in this setting was demonstrated in a 30-week, placebo-controlled study in 296 children and adolescents aged 10–17 years, who met DSM-IV criteria for bipolar I disorder with manic or mixed episodes, with or without psychotic features, and had a Young Mania Rating Scale (YMRS) score ≥20 at baseline.

Patients were randomised to receive aripiprazole 10mg or 30mg daily or placebo and were assessed for change in YMRS score at week 4 as the primary endpoint. After 4 weeks, acute treatment completers continued treatment for up to a further 26 weeks.

Superior to placebo at both doses

Both doses of aripiprazole were superior to placebo in terms of YMRS total score change from baseline at week 4 and 12 (both p<0.001). However, evidence for prevention of recurrence was not established and completion rates were low in all treatment arms.

View Abilify drug record

Further information: Otsuka

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.